Hints and tips:
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...PepsiCo Q1, Philip Morris International Q1, RWS Holdings HY, Seagate Q3, Shimano Q1, Spotify Q1, Taylor Wimpey AGM & trading update, Tesla Q1, Texas Instruments Q1, United Parcel Service Q1, Visa Q2, W R...
...Cancer, stroke and diabetes medications made by Merck, Johnson & Johnson and Bristol Myers Squibb are among the first tranche of medications selected for negotiation....
...Bristol Myers Squibb has warned of similar moves. Investors value future drugs according to their chances of success and potential market size....
...Initial Irish investments by Pfizer and Bristol Myers Squibb more than a half century ago encouraged other multinationals to follow, he said....
...From meetings with Sam Altman to a secretive “Project R”, SoftBank boss Masayoshi Son is looking to make a comeback after years and years of bad bets, The Information reports. CEO or CEOs?...
...The UK’s share of pharmaceuticals R&D has fallen, from 7.7 per cent in 2012 to 4.2 per cent in 2020....
...The chief executive of Bristol Myers Squibb called the US government’s support for the temporary waiver of Covid-19 vaccine patents “very concerning”, adding to the outcry from the pharmaceutical industry...
...They join from O’Melveny & Myers and Cooley respectively....
...The drip feed of advance announcements has already begun, partly to dull the pain of reneging on previous commitments — such as R&D spending — to meet Sunak’s fiscal targets....
...Centessa chief executive Saurabh Saha, a former senior vice-president of research and development at Bristol-Myers Squibb, said it hopes to add more biotech companies....
...“Our industry depends on intellectual property protection in order to invest in R&D and make the investments needed to address crises like Covid,” Giovanni Caforio said....
...He said the company was working on other opportunities with Novartis and also with Bristol-Myers Squibb. “We believe long-term BMS will be as important to us as Novartis has been,” he added....
...The US has no choice but to improve its infrastructure and human capital or continue its slide towards second tier status.” — Paul A Myers, Corona del Mar, California...
...The cartoonish game is less R&R, “more a place of decompression as action”, says Andrew Eiche, chief technology officer at Vacation Simulator’s developer, Owlchemy Labs....
...Companies such as Switzerland’s Roche and Merck and Bristol-Myers Squibb in the US have been developing cancer treatments that harness the body’s immune system for years....
...Moreover, it has a plan to achieve a staggering $2bn in annual efficiencies by whacking at combined R&D and overhead costs....
...“We look forward to advancing this late-stage asset as part of our broad oncology R&D programme,” said Roger Perlmutter, president of Merck Research Laboratories....
...This looks ever more likely to involve snapping up relatively under-priced biotechs in whose labs so much of the cutting edge work of R&D is now done....
...Indeed, AbbVie’s tilt at Allergan is the latest in a wave of blockbuster pharma deals this year that Bristol-Myers Squibb kicked off in January with a $74bn bid for Celgene....
...Starboard, the activist that campaigned against its purchase by Bristol-Myers Squibb, raised doubts over the blockbuster potential of some of its hotly tipped new drugs....
...The K and the R of KKR clearly had their differences over Brexit, with Roberts optimistic that a hard Brexit and a weakened sterling would create opportunities for PE....
...Mr González said the price of Humira in the US played an “important role” in funding the company’s R&D. He added that the company had issued licences to several biosimilar makers to produce Humira....
...Bristol-Myers Squibb last week agreed to a $90bn deal to buy Celgene, a biotech company with a deep portfolio of cancer-focused assets....
...But the world of fashion proves fickle and our chirpy heroine sadly turns into a hard-nosed snob, ripe to be taught a lesson by the strange Mr R....
International Edition